Tag Archives: Raju Prasad

Allogene Therapeutics Inc (ALLO) Gets a Buy Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Allogene Therapeutics Inc (ALLO – Research Report). The company’s shares opened today at $26.09. According to TipRanks.com, Prasad is a 5-star analyst with an average

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals Inc (NASDAQ: RCKT) and Zogenix (NASDAQ: ZGNX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals Inc (RCKT – Research Report) and Zogenix (ZGNX – Research Report) with bullish sentiments. Rocket Pharmaceuticals Inc (RCKT) William Blair

William Blair Sticks to Its Buy Rating for Celyad (CYAD)

William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD – Research Report) today. The company’s shares opened today at $21.87. Prasad commented: “We view 2019 as a pivotal year for the company as it determines the optimal

Crispr Therapeutics AG (CRSP) Initiated with a Hold at William Blair

Crispr Therapeutics AG (CRSP – Research Report) received a Hold rating from William Blair analyst Raju Prasad today. The company’s shares opened today at $39.71. Prasad wrote: “CRISPR Therapeutics AG We are initiating coverage on CRISPR Perform rating and $39

Allogene Therapeutics Inc (ALLO) Initiated with a Buy at William Blair

Allogene Therapeutics Inc (ALLO – Research Report) received a Buy rating from William Blair analyst Raju Prasad today. The company’s shares opened today at $26.80. Prasad commented: “Allogene Therapeutics, Inc. Just as We are initiating coverage on Outperform rating and

Rocket Pharmaceuticals Inc (RCKT) Received its Third Buy in a Row

After Oppenheimer and Cowen & Co. gave Rocket Pharmaceuticals Inc (NASDAQ: RCKT) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Rocket Pharmaceuticals Inc today. The